Cantor Fitzgerald Research Analysts Lower Earnings Estimates for Fennec Pharmaceuticals Inc. (TSE:FRX)

Fennec Pharmaceuticals Inc. (TSE:FRX – Get Rating) – Equities researchers at Cantor Fitzgerald cut their FY2023 earnings per share estimates for shares of Fennec Pharmaceuticals in a report issued on Monday, May 15th. Cantor Fitzgerald analyst C. Duncan now expects that the biopharmaceutical company will earn ($0.69) per share for the year, down from their prior estimate of ($0.63). The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.08 per share.

Get Fennec Pharmaceuticals alerts:

Fennec Pharmaceuticals Stock Performance

TSE:FRX opened at C$10.14 on Wednesday. The business’s 50-day moving average price is C$11.05 and its two-hundred day moving average price is C$12.17. Fennec Pharmaceuticals has a twelve month low of C$6.70 and a twelve month high of C$14.41. The stock has a market cap of C$267.90 million, a P/E ratio of -8.52 and a beta of 0.16. The company has a quick ratio of 10.17, a current ratio of 5.80 and a debt-to-equity ratio of 881.09.

Fennec Pharmaceuticals (TSE:FRX – Get Rating) last issued its quarterly earnings data on Thursday, March 30th. The biopharmaceutical company reported C($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of C($0.33) by C($0.02).

Fennec Pharmaceuticals Company Profile

(Get Rating)

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014.

Read More

• 5 Best Bank ETFs to Buy Now
• How to Invest in Telehealth and Telemedicine Stocks
• Target’s Guidance Looms Over The Market 
• Want Clean Energy? Siemens May Be Pointing To A Breakout
• Up Over 2,600% in 5 Years, Wall Street Still Calls Celsius a Buy

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.